dc.contributor.author | Staudinger, Jeffrey Leonard | |
dc.contributor.author | Woody, Sarah K. | |
dc.contributor.author | Sun, Mengxi | |
dc.contributor.author | Cui, Wenqi | |
dc.date.accessioned | 2017-06-12T16:29:55Z | |
dc.date.available | 2017-06-12T16:29:55Z | |
dc.date.issued | 2013-02 | |
dc.identifier.citation | Staudinger, J. L., Woody, S., Sun, M., & Cui, W. (2013). Nuclear-receptor–mediated regulation of drug– and bile-acid–transporter proteins in gut and liver. Drug Metabolism Reviews, 45(1), 48–59. http://doi.org/10.3109/03602532.2012.748793 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/24466 | |
dc.description | This is an Accepted Manuscript of an article published by Taylor & Francis in Drug Metabolism Reviews on 2015 Sep 2, available online: http://www.tandfonline.com/10.3109/03602532.2012.748793. | en_US |
dc.description.abstract | Adverse drug events (ADEs) are a common cause of patient morbidity and mortality and are classically thought to result, in part, from variation in expression and activity of hepatic enzymes of drug metabolism. It is now known that alterations in the expression of genes that encode drug- and bile-acid–transporter proteins in both the gut and liver play a previously unrecognized role in determining patient drug response and eventual clinical outcome. Four nuclear receptor (NR) superfamily members, including pregnane X receptor (PXR, NR1I2), constitutive androstane receptor (NR1I3), farnesoid X receptor (NR1H4), and vitamin D receptor (NR1I1), play pivotal roles in drug- and bile-acid– activated programs of gene expression to coordinately regulate drug- and bile-acid transport activity in the intestine and liver. This review focuses on the NR-mediated gene activation of drug and bile-acid transporters in these tissues as well as the possible underlying molecular mechanisms. | en_US |
dc.publisher | Taylor & Francis | en_US |
dc.subject | Pregnane x receptor | en_US |
dc.subject | Constitutive androstane receptor | en_US |
dc.subject | Farnesoid x receptor | en_US |
dc.subject | Vitamin D receptor | en_US |
dc.subject | Cholestasis | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Liver disease | en_US |
dc.subject | Adverse drug events | en_US |
dc.subject | Drug interactions | en_US |
dc.title | Nuclear-receptor–mediated regulation of drug– and bile-acid–transporter proteins in gut and liver | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Staudinger, Jeff L. | |
kusw.kuauthor | Woody, Sarah | |
kusw.kuauthor | Sun, Mengxi | |
kusw.kuauthor | Cui, Wenqi | |
kusw.kudepartment | Pharmacy | en_US |
kusw.oanotes | Per SHERPA/RoMEO 6/12/2017: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing)
Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: cross author cannot archive publisher's version/PDF
General Conditions: Some individual journals may have policies prohibiting pre-print archiving
On author's personal website or departmental website immediately
On institutional repository, subject-based repository or academic social network (Mendeley, ResearchGate or Academia.edu) after 12 months embargo
Publisher's version/PDF cannot be used
On a non-profit server
Published source must be acknowledged
Must link to publisher version
Set statements to accompany deposits (see policy)
The publisher will deposit in on behalf of authors to a designated institutional repository including PubMed Central, where a deposit agreement exists with the repository | en_US |
dc.identifier.doi | 10.3109/03602532.2012.748793 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC4557796 | en_US |
dc.rights.accessrights | openAccess | |